DECATUR, Ga. Fall Festival season, football season, Pumpkin Spice season thats just a sample of seasons that were entering. DeKalb health officials want to make sure another season is top of mind for everyone flu season.
To that end, the DeKalb County Board of Health is hosting a drive-thru flu vaccination event on Sat., Sept. 17, from 8:00 a.m. until noon, at Dunwoody High School.
This event is focused on adults aged 18 and older, seniors aged 65 and older who may need a high-dose vaccine for added protection, individuals who are immunocompromised or have chronic health conditions (such as asthma, diabetes, and heart disease), and pregnant women. Pediatric flu vaccines will be given at our regional health center locations during regular business hours.
All patients should bring their insurance information and photo ID. Flu shots are available at no cost with most private insurance and Medicare. The Board of Health accepts Aetna, Amerigroup, Anthem Blue Cross and Blue Shield, Cigna, Medicaid, Medicare Part B, Peach State Health Plan (including PeachCare for Kids), and State Health Benefit Plan (excluding Kaiser Permanente). If you are not insured or your plan doesnt cover the flu shot, its available for a low cost. Cash, checks drawn on banks with branch locations in Georgia, and credit/debit cards are accepted. Other insurances may be accepted, but you are asked to call ahead to verify acceptance.
After this event, flu shots will be available on an appointment and walk-in basis Monday through Friday between 8:15 a.m. and 4:30 p.m., excluding holidays recognized by the State of Georgia, at the following regional health center locations:
For more information about the flu or the DeKalb County Board of Healths immunization programs, including onsite worksite or community flu clinics, visit dekalbhealth.net/flu or call 404-294-3700.
DUBLIN--(BUSINESS WIRE)--The "Global Influenza Vaccine Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
The global Influenza Vaccine market is expected to grow at a compound annual growth rate of 5.35% over the forecast period to reach a market size of US$6.017 billion in 2027 from US$4.177 billion in 2020.
Introduction
Influenza is a viral infection that affects the respiratory system and is caused by the flu virus. The influenza virus is infectious and spreads by respiratory droplets. It can also be passed from one person to another through conversation or physical touch. The influenza virus is constantly spreading, resulting in regional epidemics and outbreaks that kill thousands of people. Healthcare organisations like the Centers for Disease Control and Prevention (CDC) around the world are using vaccines like baloxavir marboxil (Xofluza) to treat the flu caused by the influenza virus. The rising prevalence of Sars-cov-2 across the globe and the rising investments in research and development to develop a vaccine that can fight against the COVID-19 virus are expected to drive the influenza vaccine market during the forecast period. According to the World Health Organization, annual influenza epidemics are estimated to severely affect 3-5 million people and cause 290k to 650k respiratory deaths. The growing geriatric population across the globe is also expected to increase the demand for influenza vaccines as people aged over 60 years are at greater risk of severe disease or health complications caused by the influenza virus.
Market Trends
Diabetes, cancer, anemia, obesity, immune deficiencies, human immunodeficiency virus (HIV), metabolic diseases, kidney disease, neurological disorders, and chronic heart and lung disorders like bronchopulmonary dysplasia, cystic fibrosis, and asthma are all increasing the risk of contracting influenza. This is a significant role in the market's expansion.
Furthermore, children under the age of five are at a higher risk of developing complications such as high fever, seizures, and pneumonia. This, together with increased parental concerns about their children's health, is impacting influenza vaccine demand in a good way. Growing awareness about the medication and prevention of influenza and an increasing number of government initiatives will further drive the growth of the market in the coming years.
Growth Factor
The rising prevalence of influenza and the growing influenza vaccination drive
The centre for Disease Control and Prevention has estimated the number of people who fall ill because of the flu and calculated that around 9 to 41 million people were severely ill because of the flu caused by the influenza virus. About 140,000 - 710,000 people were hospitalised due to health-related complications caused by the influenza virus, and 12,000 - 52,000 deaths occured annually between 2010 and 2020.
The increasing global demand for coupled inductors has led to the entry of several new players in the global influenza vaccine market. To increase their clientele as well as increase their market share in the upcoming years, many of these market players have taken various strategic actions like partnerships and the development of novel solutions, which are expected to keep the market competitive and constantly evolving. Major market players like Seqirus, GlaxoSmithKline PLC, and Sanofi Pasteur SA, among others, have been covered along with their relative competitive strategies. The report also mentions recent deals and investments by different market players over the last few years.
Segmentation:
By Vaccine Technology
By End-User
By Geography
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Global Influenza Vaccine Market, By Vaccine Technology
6. Global Influenza Vaccine Market, By End-User
7. Global Influenza Vaccine Market, By Geography
8. Competitive Environment and Analysis
9. Company Profiles.
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/lwdih5
Before COVID-19, influenza was the infection mostwell-knownfor causing pandemics.
Influenza virus is subdivided into types (A, B, and rarely C and D). Influenza A is further classified into subtypes based on haemagglutinin (H) and neuraminidase (N) protein variants on the surface of the virus. Currently, the most common influenza strains in humans are A/H1N1 and A/H3N2.
Zoonotic infectionoccurs when influenza strains that primarily affect animals spill over to humans.
Major changes in the influenza virus usually result fromnew combinationsof influenza viruses that affect birds, pigs and humans. New strains have the potential to cause pandemics as there is little pre-existing immunity.
Since the beginning of the 20th century, there have been four influenzapandemics, in 1918, 1957, 1968, and 2009. In between pandemics, seasonal influenza circulates throughout the world.
Although influenza is not as infectious as many other respiratory infections, the very short incubation period of around 1.4 days means outbreaks can spread quickly.
Vaccines are available to prevent influenza, but are onlypartiallyprotective. Antiviral treatments are available, including oseltamivir, zanamivir, peramivir and baloxavir. Oseltamivirdecreasesthe duration of illness by around 24 hours if started early, but whether it reduces the risk of severe influenza and its complications iscontroversial.
Allen Cheng
Register now for FREE unlimited access to Reuters.comRegister
ROUZIC ISLAND, France, Sept 7 (Reuters) - The island of Rouzic's windswept clifftops should be teeming with gannets, but an unseasonal wave of bird flu on the French Atlantic coast this summer has devastated their numbers, alarming conservationists and poultry farmers.
Thousands of seabirds have perished along France's western shores in past weeks because of the viral infection, which usually strikes during autumn and winter months, raising fears it may have become a year-round risk and endemic to French wildlife.
That poses a danger for France's poultry industry, the European Union's second largest, which was forced to cull more than 19 million birds between November and May because of avian influenza, as bird flu is formally called.
Register now for FREE unlimited access to Reuters.comRegister
"Bird flu is hitting seabirds in the spring and in the summer, which is totally new. Traditionally bird flu mainly hits waterfowls during winter," Pascal Provost, director of the Sept-Iles archipelago bird reserve which includes the Rouzic island.
After a brief lull in farm outbreaks in May, the French government eased poultry farming curbs in June. read more
However, soon after the virus hit flocks along the Brittany coast, slowly spreading south.
Rouzic is home to one of the world's rare colonies of northern gannets. Provosts said bird flu ravaged the flock from early July, killing adults and leaving their chicks to starve.
Since late July, seven new bird flu outbreaks have been confirmed on French farms, according to the agriculture ministry.
"The situation is exceptional - never encountered in France before - due to its scale and the period when cases are being detected," the ministry said on its website, warning about the risk of contamination to poultry farms.
French poultry farmers are still recovering from previous outbreaks and the mass culling that followed, and before the latest outbreaks already faced a near 10% fall in output this year, industry group Anvol said.
"Before, bird flu outbreaks were caused by migrating birds, but now we see that there are more and more cases in French wildlife. This is new and it worries farmers and the whole poultry industry", Anvol chairman Jean-Michel Schaeffer told Reuters.
Bird flu is usually transmitted by infected migrating wild birds' faeces or direct contact with contaminated feed, clothing and equipment.
Register now for FREE unlimited access to Reuters.comRegister
Reporting by Stephane Mahe and Sybille de La Hamaide; Editing by Emelia Sithole-Matarise
Our Standards: The Thomson Reuters Trust Principles.
Sometime in the spring of 2020, after centuries, perhaps millennia, of tumultuous coexistence with humans, influenza abruptly went dark. Around the globe, documented cases of the viral infection completely cratered as the world tried to counteract SARS-CoV-2. This time last year, American experts began to fret that the flus unprecedented sabbatical was too bizarre to last: Perhaps the group of viruses that cause the disease would be poised for an epic comeback, slamming us with a little more punch than usual, Richard Webby, an influenza expert at St. Jude Childrens Research Hospital, in Tennessee, told me at the time.
But those fears did not not come to pass. Flus winter 2021 season in the Southern Hemisphere was once again eerily silent; in the north, cases sneaked up in Decemberonly to peter out before a lackluster reprise in the spring.
Now, as the weather once again chills in this hemisphere and the winter holidays loom, experts are nervously looking ahead. After skipping two seasons in the Southern Hemisphere, flu spent 2022 hopping across the planets lower half with more fervor than its had since the COVID crisis began. And of the three years of the pandemic that have played out so far, this one is previewing the strongest signs yet of a rough flu season ahead.
Its still very possible that the flu will fizzle into mildness for the third year in a row, making experts gloomier suspicions welcomingly wrong. Then again, this year is, virologically, nothing like the last. Australia recently wrapped an unusually early and very significant season with flu viruses, says Kanta Subbarao, the director of the WHO Collaborating Centre for Reference and Research on Influenza at the Doherty Institute. By sheer confirmed case counts, this season was one of the countrys worst in several years. In South Africa, its been a very typical flu season by pre-pandemic standards, which is still enough to be of note, according to Cheryl Cohen, a co-head of the countrys Centre for Respiratory Disease and Meningitis at the National Institute for Communicable Diseases. After a long, long hiatus, Subbarao told me, flu in the Southern Hemisphere is certainly back.
Read: The pandemic broke the flu
That does not bode terribly well for those of us up north. The same viruses that seed outbreaks in the south tend to be the ones that sprout epidemics here as the seasons do their annual flip. I take the south as an indicator, says Seema Lakdawala, a flu-transmission expert at Emory University. And should flu return here, too, with a vengeance, it will collide with a population that hasnt seen its likes in years, and is already trying to marshal responses to several dangerous pathogens at once.
The worst-case scenario wont necessarily pan out. What goes on below the equator is never a perfect predictor for what will occur above it: Even during peacetime, were pretty bad in terms of predicting what a flu season is going to look like, Webby, of St. Jude, told me. COVID, and the worlds responses to it, have put experts few forecasting tools further on the fritz. But the souths experiences can still be telling. In South Africa and Australia, for instance, many COVID-mitigation measures, such as universal masking recommendations and post-travel quarantines, lifted as winter arrived, allowing a glut of respiratory viruses to percolate through the population. The flu flood also began after two essentially flu-less yearswhich is a good thing at face value, but also represents many months of missed opportunities to refresh peoples anti-flu defenses, leaving them more vulnerable at the seasons start.
Some of the same factors are working against those of us north of the equator, perhaps to an even greater degree. Here, too, the population is starting at a lower defensive baseline against fluespecially young children, many of whom have never tussled with the viruses. Its very, very likely that kids may end up disproportionately hit, Webby said, as they appear to have been in Australiathough Subbarao notes that this trend may have been driven by more cautious behaviors among older populations, skewing illness younger.
Interest in inoculations has also dropped during the pandemic: After more than a year of calls for booster after booster, people have a lot of fatigue, says Helen Chu, a physician and flu expert at the University of Washington, and that exhaustion may be driving already low interest in flu shots even further down. (During good years, flu-shot uptake in the U.S. peaks around 50 percent.) And the few protections against viruses that were still in place last winter have now almost entirely vanished. In particular, schoolsa fixture of flu transmissionhave loosened up enormously since last year. Theres also just much more flu around, all over the global map, Webby said. With international travel back in full swing, the viruses will get that many more chances to hopscotch across borders and ignite an outbreak. And should such an epidemic emerge, with its health infrastructure already under strain from simultaneous outbreaks of COVID, monkeypox, and polio, America may not handle another addition well. Overall, Chu told me, we are not well prepared.
Read: The most important vaccine Ill get this fall
At the same time, though, countries around the world have taken such different approaches to COVID mitigation that the pandemic may have further uncoupled their flu-season fate. Australias experience with the flu, for instance, started, peaked, and ended early this year; the new arrival of more relaxed travel policies likely played a role in the outbreaks beginning, before a mid-year BA.5 surge potentially hastened the sudden drop. Its also very unclear whether the U.S. may be better or worse off because its last flu season was wimpy, weirdly shaped, and unusually late. South Africa saw an atypical summer bump in flu activity as well; those infections may have left behind a fresh dusting of immunity and blunted the severity of the following season, Cohen told me. But its always hard to tell. I was quite strong in saying that I really believed that South Africa was going to have a severe season, she said. And it seems that I was wrong. The long summer tail of the Northern Hemispheres most recent flu season could also exacerbate the intensity of the coming winter season, says John McCauley, the director of the Worldwide Influenza Centre at the Francis Crick Institute, in London. Kept going in their off-season, the viruses may have an easier vantage point from which to reemerge this winter.
COVIDs crush has shifted flu dynamics on the whole as well. The pandemic squeezed out a lot of diversity from the influenza-virus population, Webby told me; some lineages may have even entirely blipped out. But others could also still be stewing and mutating, potentially in animals or unmonitored pockets of the world. That these strainswhich harbor especially large pandemic potentialcould emerge into the general population is my bigger concern, Lakdawala, of Emory, told me. And although the particular strains of flu that are circulating most avidly seem reasonably well matched to this years vaccines, the dominant strains that attack the north could yet shift, says Florian Krammer, a flu virologist at Mount Sinais Icahn School of Medicine. Viruses also tend to wobble and hop when they return from long vacations; it may take a season or two before the flu finds its usual rhythm.
Another epic SARS-CoV-2 variant could also quash a would-be influenza peak. Flu cases rose at the end of 2021, and the dreaded twindemic loomed. But then, Omicron hitand flu basically disappeared for one and a half months, Krammer told me, only tiptoeing back onto the scene after COVID cases dropped. Some experts suspect that the immune system may have played a role in this tag-team act: Although co-infections or sequential infections of SARS-CoV-2 and flu viruses are possible, the aggressive spread of a new coronavirus variant may have set peoples defenses on high alert, making it that much harder for another pathogen to gain a foothold.
Read: Dont worry, its not the flu
No matter the odds we enter flu season with, human behavior can still alter winters course. One of the main reasons that flu viruses have been so absent the past few years is because mitigation measures have kept them at bay. People understand transmission more than they ever did before, Lakdawala told me. Subbarao thinks COVID wisdom is what helped keep Australian flu deaths down, despite the gargantuan swell in cases: Older people took note of the actions that thwarted the coronavirus and applied those same lessons to flu. Perhaps populations across the Northern Hemisphere will act in similar ways. I would hope that weve actually learned how to deal with infectious disease more seriously, McCauley told me.
But Webby isnt sure that hes optimistic. People have had enough hearing about viruses in general, he told me. Flu, unfortunately, does not feel similarly about us.
A recently launched clinical trial at Penn Medicine will evaluate a new chewing gum designed by School of Dental Medicine researchers to trap SARS-CoV-2 in the saliva, potentially blocking transmission of COVID-19 from one person to another.
The trial will recruit participants from a pool of Penn Medicine employees whose responses to the PennOpen Pass screening system indicate that they may be battling a COVID-19 infection. Those who enroll in the clinical trial will be given a packet of a dozen experimental tablets of gum. Each morning, theyll pop one in their mouthand start to chew.
The cinnamon-flavored gum is designed to do far more than freshen breath. Thanks to innovations emerging from the lab of School of Dental Medicine researcher Henry Daniell, the experimental gum contains plant-derived material genetically engineered to contain ACE2, a protein found naturally in human blood and saliva. The ACE2 receptor is found on human cells and is bound by SARS-CoV-2 virus during infection. In experimental models, chewing the gum was found to release the embedded ACE2, blocking the interaction of the chewers own ACE2 receptor and the viral spike protein.
In effect, the gum is designed to trap and neutralize SARS-CoV-2 in the saliva and, ideally, diminish the amount of virus left in the mouth. It is hoped that less virus would mean a lower likelihood of passing the infection on to others.
Daniell and colleagues are also working on another gum, containing a different protein that could target a broader range of respiratory viruses, including influenza.
Im hoping that if this is effective and safe it will be the beginning of several other oral delivery drugs, using this platform, says Daniell, the vice chair and W. D. Miller Professor in Penn Dental Medicines Department of Basic and Translational Sciences.
Findings from a pre-clinical study of the gums efficacy in neutralizing SARS-CoV-2 and influenza virus in patient samples, published in the journal Biomaterials in July, showed it could reduce viral load to nearly undetectable levels. The results supported an application to the U.S. Food and Drug Administration (FDA) for an Investigational New Drug, which went into effect in May and paved the way for the launch of the clinical trial at Penn Medicine.
The technology behind this experimental treatment has moved from the laboratory bench toward the beginning of clinical experimentation, all within Penn Dental Medicine, a first for the school. The partnership with colleagues from Penn Medicine enables the launch of the first-in-human clinical trial.
This technology may have the ability to reduce the spread of COVID-19 and the flu as well as make it safer for dentists and other healthcare providers to provide care to patients who we know are infected, says Mark Wolff, the Morton Amsterdam Dean of Penn Dental Medicine, who was also a coauthor on the Biomaterials study.
For years, Daniell has used his plant-based platform to generate a range of biomolecules with both therapeutic and commercial potential. Prior to the COVID-19 pandemic, one of the proteins his lab had explored was ACE2, originally with a view toward evaluating its impact on pulmonary hypertension.
As the pandemic began, ACE2 began receiving significant attention for a different reason: its receptor provides the docking station for the spike protein of SARS-CoV-2. Suddenly, Daniells work had found a new potential application: as a trap for the virus that causes COVID-19.
Daniell had already been working on protein drug delivery approach via a chewing gum, and, given that the SARS-CoV-2 virus replicates in the salivary glands, delivering ACE2 to the mouth with a gum appeared to him to be a potentially powerful approach.
Another coincidence augmented the potential of the viral trap approach. During infection, not only does the SARS-CoV-2 spike protein bind to the host cells ACE2 receptor, but two other co-receptors on the virus, known as GM-1 receptors, facilitate the binding process. CTB, a protein that Daniell had already been evaluating in his ACE2 biotherapeutic, turns out to also bind GM-1, thus serving as an additional lure in the context of SARS-CoV-2 infection.
In a Molecular Therapy paper published in November 2021, Daniell and colleagues showed in pre-clinical studies that a chewing gum containing CTB and ACE2 could reduce SARS-CoV-2 viral loads in saliva obtained from COVID-19 patients under experimental conditions. The Biomaterials paper extended that work, using samples from the delta and omicron waves of the pandemic to demonstrate that the gum could neutralize these strains under these same in vitro conditions as well.
The latter publication also went beyond COVID to consider how such a gum might potentially block a broader cross-section of viruses, including those that dont rely on the ACE2 receptor to enter cells.
I was very keen on developing this chewing gum delivery system to trap many different oral viruses, says Daniell, and was looking for a way to broaden the approach.
To do so, Daniell and colleagues developed a gum containing a different protein, called FRIL, which is found naturally in the plant Lablab purpureus, also known as the Lablab or hyacinth bean. While the spike-ACE2 receptor interaction is specific to coronavirus, FRIL binds to molecules called complex-type N-glycans, which are found on a broader spectrum of viruses, including SARS-CoV-2 and influenza viruses.
The research team used two different assays to evaluate the in vitro performance of the FRIL and CTB-ACE2 chewing gums; one, a microbubbling test developed by the Perelman School of Medicines Ping Wang; the other, an electrochemical sensing test invented by Cesar de la Fuente of Penn Medicine and the School of Engineering and Applied Science. Both tests confirmed that the gum could significantly reduce viral levels in patient samples.
Throughout the stages of evaluating the gum, Daniell and Penn Dental Medicine colleagues have worked in close collaboration with researchers from around Penn, particularly in the Perelman School of Medicine, enabling the work to take on special relevancy in the context of the evolving COVID pandemic. In addition to Wang and de la Fuentes testing platforms playing a role in evaluating the technology, Ronald Collman, a professor of medicine, helped collect COVID-positive samples with which to test the gum. Frederic Bushman, a microbiology professor, sequenced the viral samples to determine which strain of SARS-CoV-2 they represented. And Penn Medicine infectious disease specialists Pablo Tebas and William Short are the leader investigators for the phase 1/2 clinical trial and the Perelman School of Medicine is serving as the regulatory sponsor for the clinical trial.
The trial aims to enroll 40 participants. Each will receive gum tablets to chew and tubes for collecting saliva over the course of three days. The plant material for the trial is being produced and grown at Fraunhofer, a research and development organization, before being further processed at Penn Dental Medicine, using a freeze drier machine that meets FDA regulations to process the lettuce and ready it for incorporating into gum tablets.
Each day participants will chew four tablets of gum, and take eight samples of saliva, before and after chewing, says Daniell. On the fourth day, theyll come to the clinic, chew a final tablet of gum, and get an examination, record their symptoms, and submit their samples.
The phase 1/2 trial will be used to ensure the gum is safe to use. Each of the participants saliva samples will undergo multiple PCR tests to quantify the level of virus present.
With the gum, Daniell hopes to develop a tool that can complement others, such as vaccines and antivirals, to make a further dent in this pandemicand perhaps future ones. He points out that the gum represents the first Investigational New Drug submission for a human therapeutic protein drug that doesnt require a cold chain or protein purification. Eliminating the protein purification stepmade possible because of the protein being grown in plantsreduces costs dramatically. And being shelf-stable means the gum could more easily reach remote and less developed areas of the world without need of refrigeration or special handling.
To one day reach this scale, Daniell has partnered with Penn Center for Innovation (PCI) to spin out this technology into a Penn startup company. Michael Poisel, who manages PCI Ventures, a division of PCI that works directly with researchers help form and launch new startups based on Penn technologies, says Daniells desire for broad and global accessibility has been a primary motivation behind the development of the gum and other products, from their initial promise in the lab to the clinical trial ongoing today.
One of the exciting things about the technology is the potential to help people in countries that dont have the resources to benefit as broadly from the current vaccines and other therapies, Poisel says. Henry is really focused on making sure we can offer this in a cost-effective manner so the gum, once FDA approved, could be distributed as widely as possible and benefit as many people as possible.
Henry Daniell is vice chair and the W. D. Miller Professor in the Department of Basic and Translational Sciences in the University of Pennsylvania School of Dental Medicine.
Mark Wolff is the Morton Amsterdam Dean in Penns School of Dental Medicine.
Michael Poisel is executive director of PCI Ventures at Penn.
Daniells coauthors on the Biomaterials paper were Penn Dental Medicines Smruti K. Nair, Hancheng Guan, Yuwei Guo, Rachel J. Kulchar, Geetanjali Wakade, Fracis K. Mante, Robert P. Ricciardi, and Mark Wolff; the Perelman School of Medicines Marcelo D. T. Torres, Andrew D. Marques, Jevon Graham-Wooten, Wan Zhou, Ping Wang, Sudheer K. Molugu, Cesar de la Fuente-Nunez, William R. Short, Pablo Tebas, Kenneth B. Margulies, Frederic Bushman, and Ronald G. Collman; Taiwan Academy of Sciences Md. Shahed-Al-Mahmud, Yo-Min Liu , and Che Ma; and Brazils State University of CampinasUNICAMPs William R. de Araujo.
Daniell is a patentee in this field and the co-founder of a Penn spinout company seeking to further develop certain Penn-owned intellectual property relating to this program. Relevant information on patents and applications is available online.
The work was supported primarily by the National Institutes of Health (HL107904, HL109442, HL133191, HL137063), the Commonwealth of Pennsylvania, Penn Center for Precision Medicine, Penn Health-Tech, the Center for Innovation & Precision Dentistry, and the Taiwan Ministry of Science and Technology.
DUBLIN--(BUSINESS WIRE)--The "Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Vaccine Type, Virus Type, Technology, and Route of Administration" report has been added to ResearchAndMarkets.com's offering.
The influenza vaccines market is expected to grow from US$ 7,478.53 million in 2021 to US$ 12,272.49 million by 2028. It is expected to grow with a CAGR of 7.4% from 2022 to 2028.
Increasing government support to promote influenza vaccination and rising investment by top market players and governments are the major factors boosting the market.
The governments of various states are supporting the promotional activities of vaccination program. For instance, the Australian government gives a free seasonal influenza vaccine to those at risk of influenza-related complications through the National Immunization Program (NIP). By 2022, enough vaccines have been given to cover all risk groups eligible for a government-funded flu vaccine through the NIP.
Vaccine Type Insights
Based on the vaccine type, the influenza vaccines market is segmented into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment is likely to hold a larger market share in 2022.
The same segment is anticipated to register a higher CAGR during the forecast period. The quadrivalent influenza (flu) vaccine protects against 4 influenza viruses, including 2 influenza A viruses and 2 influenza B viruses. All flu vaccines in the US during the 2021-2022 season are quadrivalent vaccines. Different vaccines are approved for different age groups.
Virus Type Insights
Based on virus type, the influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment is likely to hold a larger market share in 2022. The same segment is expected to record a faster CAGR during the forecast period. The market growth of the influenza virus type A segment is because it is the most common form of influenza and can infect animals, although illnesses associated with this type of flu are more common.
Technology Insights
Based on technology, the influenza vaccines market is segmented into egg-based and cell-based. The egg-based segment is likely to hold a larger market share in 2022. The same segment is expected to record a faster CAGR during the forecast period.
The market growth of the egg-based segment is due to its most common method of producing flu vaccines through an egg-based manufacturing process that has been used for more than 70 years.
Route of Administration Insights
Based on route of administration, the influenza vaccines market is segmented into injection and nasal spray. The injection segment is likely to hold a larger market share in 2022. The same segment is expected to register a higher CAGR during the forecast period.
The market growth of the injection segment is attributed to the fact that it is the most common method for flu vaccine administration.
Key Topics Covered:
1. Introduction
2. Influenza Vaccines Market - Key Takeaways
3. Research Methodology
4. Influenza Vaccines Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. Global Influenza Vaccines Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Government Support to Promote Influenza Vaccination
5.1.2 Increasing Investment by Top Market Players and Governments
5.2 Market Restraints
5.2.1 High Cost of Vaccine Development
5.3 Market Opportunities
5.3.1 Emerging Economies
5.4 Future Trends
5.4.1 Strong Pipeline Candidates for Influenza Vaccines
5.5 Impact Analysis
6. Influenza Vaccine Market -Global Analysis
6.1 Global Influenza Vaccines Market Revenue Forecasts And Analysis
6.2 Global Influenza Vaccines Market, By Geography - Forecasts And Analysis
6.3 Global Influenza Vaccines Market - Market Potential Analysis, By Region
6.4 Company Analysis
6.4.1 Market Positioning of Key Players
6.4.2 Comparative Company Analysis
6.5 Growth Strategy Analysis
6.6 Performance of Key Players
6.6.1 Sanofi
6.6.2 SEQIRUS
7. Influenza Vaccines Market Analysis and Forecasts To 2028 - By Vaccine Type
7.1 Overview
7.2 Global Influenza Vaccines Market, By Vaccine Type 2022 & 2028 (%)
7.3 Quadrivalent Vaccines
7.4 Trivalent Vaccines
8. Influenza Vaccines Market Analysis and Forecasts To 2028 - By Virus Type
8.1 Overview
8.2 Global Influenza Vaccines Market, By Virus Type 2022 & 2028 (%)
8.3 Influenza Virus Type A
8.4 Influenza Virus Type B
9. Influenza Vaccines Market Analysis and Forecasts To 2028 - By Technology
9.1 Overview
9.2 Global Influenza Vaccines Market, By Technology 2022 & 2028 (%)
9.3 Egg-based
9.4 Cell-based
10. Influenza Vaccines Market Analysis and Forecasts To 2028 - By Route of Administration
10.1 Overview
10.2 Global Influenza Vaccines Market, By Route of Administration 2022 & 2028 (%)
10.3 Injection
10.4 Nasal Spray
11. Influenza Vaccines Market Analysis and Forecasts To 2028 - Geographical Analysis
12. Impact of COVID-19 Pandemic on Global Influenza Vaccines Market
13. Influenza Vaccine Market -Industry Landscape
13.1 Overview
13.2 Growth Strategies in the Influenza Vaccine Market, 2021-2028
13.3 Inorganic Growth Strategies
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Key Facts
14.2 Business Description
14.3 Products and Services
14.4 Financial Overview
14.5 SWOT Analysis
14.6 Key Developments
For more information about this report visit https://www.researchandmarkets.com/r/1ye6sv
Simon O'Connor/Stuff
During the winter 253 people were hospitalised in Taranaki Base Hospital with Covid.
The health forecast for winter was all doom and gloom, but the outlook for spring and summer is much better.
Cough and cold viruses normally take a holiday over summer, Te Whatu Ora Taranaki medical officer of health Dr Jonathan Jarman said in an emailed response to questions.
This is partly because of the weather and the behaviour of humans; during summer people are out and about, windows are open, and we are not spending a lot of time close to other people like we do in winter.
However, he said its important to note that Covid-19 was not going away.
READ MORE:* Staff illness sees Taranaki hospitals restrict visitor numbers and reduce care services* Covid-19, flu causing dire staffing situation for Taranaki hospitality businesses* Covid-19 NZ: Are we speeding towards a 'twindemic'?
There are likely to be ongoing infections throughout summer, though at a lower rate than the peak of winter.
People are still dying because of Covid-19, Jarman said.
And wastewater surveillance testing shows that the Covid-19 virus is still out there.
As of Tuesday, 74 people in Taranaki have died with Covid being the underlying cause of death or a contributory cause of death.
During winter, 253 people were hospitalised in Taranaki with Covid 73 in June, 113 in July, dropping to 67 in August.
From the peak of more than 500 cases a day in March there 45 new cases of the virus on Tuesday.
Stuff
Te Whatu Ora Taranaki medical officer of health Jonathan Jarman says cough and cold viruses normally take a holiday over summer.
While there are now only 299 active cases of Covid in the region, 45,131 or 36.8% of the population, in Taranaki have had the virus. Nationally, more than 50% of the population have been infected.
Medical experts predicted a tridemic made up of Covid, the flu and a respiratory illness called RSV could hit over winter.
And while winter was challenging,, RSV didnt really make an appearance, Jarman said.
It is possible that the rates of illness last year caused enough protection at a population level to protect people this year.
Flu was predicted to come back with a vengeance, but it didnt reach the same levels as it did in 2019, before lockdowns and border closures put it on hold.
There were 108 people hospitalised with the flu in Taranaki during winter 55 in June, 50 in July and 3 in August.
This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.
DC District Court of Appeals | YouTube screenshot
WASHINGTON The National Nurses United and the AFL-CIO are disappointed by another federal appellate court ruling bouncing their demand the government permanently force firms to protect workers against the coronavirus.
On August 26, the U.S. Court of Appeals for D.C., said it lacked the jurisdiction to force the Occupational Safety and Health Administration (OSHA) to move.
And Judge Neomi Rao, a 2019 Trump appointee with a Republican and right-wing pedigree, said NNU and its allies wanted a preordained resulta permanent OSHA standard forcing health care firms to protect workers against the viruswithin 30 days.
NNU also wanted OSHA to reinstate its emergency temporary standard, suspended last December after another D.C. Circuit panel tossed it. OSHA said then it would work on creating and announcing a permanent standard. Judge Rao sneeringly slammed both requests.
We cant force that, Rao wrote for herself and two panel colleagues. One of them, the courts chief judge, David Sentelle, was a Republican appointee, like her.
NNU sought a writ of mandamusLatin for a mandateto get OSHA to act. Rao said such mandates are reserved only for transparent violations of a clear duty to act. OSHAs not doing that, Rao declared. Instead, she opined, OSHAs following its usual rulemaking drill. She ducked the point that such formal procedures often take years, due to corporate opposition.
Besides, OSHA can still come to the conclusion that it doesnt need a permanent standard to protect workers against the virus, the judge said. And enforcement of the healthcare ETS is squarely within OSHAs prosecutorial discretion, she added.
Raos ruling upset both NNU, the lead union in both cases, and the AFL-CIO.
This wasnt the result we were hoping forand we arent giving up, NNU Assistant Director Of Nursing Michelle Mahon, RN, wrote in an e-mailed request for petition signatures demanding OSHA issue a permanent anti-virus standard.
The pandemic is still ongoing, with nurses and other health care workers on the frontlines. As of today, nearly 500 registered nurses and more than 4,800 other health care workers have died due to Covid-19, and many more are suffering from long Covid.
Without the protections provided by a permanent standard, nurses and other health care workers are in grave danger. We have to increase the pressure on OSHA to act now:will you add your name to our urgent petition demanding OSHA pass a permanent standard? she asked. Its at act.nnu.org.
To safely care for us and our loved ones, nurses need to have personal protective equipment, proper testing and isolation practices, and infection control protocols in place. OSHAs permanent standard would guarantee these protections, sowe have to make them hear us, Mahon said.
Leaving discretion with the agency to issue an anti-virus standard at a time when U.S. health care worker deaths from Covid-19 are at the highest point since early 2021 disappointed AFL-CIO President Liz Shuler. OSHA should swiftly complete and issue the permanent rule it announced in December when OSHA stopped enforcing emergency protections, and return to enforcing emergency protections, she added.
